Skip to main content
. Author manuscript; available in PMC: 2013 May 9.
Published in final edited form as: Biochem Biophys Res Commun. 2010 Jan 12;392(2):207–211. doi: 10.1016/j.bbrc.2010.01.016

Fig. 4.

Fig. 4

JTE-013 decreased the incidence of diabetes. JTE-013 (4 mg/kg) or saline was intraperitoneally injected for 6 days (one shot prior to STZ and five shots with a high dose of STZ (50 mg/kg)). (A) Changes in blood glucose levels of randomly fed mice with/without STZ or JTE-013 injection. Sample numbers are 14 for +STZ/−JTE-013 (closed circles), +STZ/+JTE-013 (closed squares), −STZ/−JTE-013 (open circles), and −STZ/+JTE-013 (open squares). The effects of JTE-013 were significant at the 4th weeks after the final STZ injection (*P < 0.01). (B) Kaplan-Meier analysis of diabetes-free rates after STZ injection. Co-injection with JTE-013 significantly reduced the diabetes-free rates (*P < 0.01).